News and Events

Rambam HCC Treats First Patient with Innovative Alpha-Radiation Cancer Therapy

Publication Date: 6/28/2022

Rambam Health Care Campus treated the first-ever prostate cancer patient with innovative alpha-radiation cancer therapy – Alpha DaRT developed by Alpha Tau Medical Ltd.

Dr. Tomer Charas, Head of Genitourinary Oncology Unit in the Division of Oncology at Rambam HCC. Photography: Rambam HCCDr. Tomer Charas, Head of Genitourinary Oncology Unit in the Division of Oncology at Rambam HCC. Photography: Rambam HCC

The first patient at Rambam Health Care Campus (Rambam HCC) in Haifa, Israel was treated in a feasibility study with the Alpha DaRT. Alpha DaRT is a neoadjuvant therapy (the first step in attempting to shrink a tumor before the main treatment) for patients with prostate cancer. The Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), developed by Israeli medical device company, Alpha Tau Medical Ltd., delivers radium-224 directly into a solid tumor. The main idea behind this innovative therapy is to destroy the tumor while sparing the healthy tissue around it.

Rambam HCC is leading this trial in collaboration with the Carmel Urology team at Carmel Medical Center in Haifa, Israel.

Dr. Tomer Charas, head of Rambam’s Genitourinary Oncology Unit in the Division of Oncology, an attending physician in the Radiation Therapy Unit, and principal investigator of the study, commented, “We are excited to be leading this trial in collaboration with the Carmel Urology team, and to be the first to evaluate Alpha DaRT in prostate cancer in patients. Based on the results from preclinical studies, it is possible that neoadjuvant treatment with the Alpha DaRT may also trigger an immune response, which could help decrease the risk of tumor recurrence. In addition, a preferable safety profile has been observed to date in treatments of other tumor types.”